Tao Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tao Wang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Jianmin Yang
Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai 200433, China
7 shared publications Wenqin Yue
Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, China
6 shared publicationsLei Gao
Department of Hematology, Institute of Hematology, Shanghai Changhai Hospital Naval Medical University Shanghai China
5 shared publicationsYang Wang
Institute of Hematology
5 shared publicationsGusheng Tang
Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, China
4 shared publicationsJie Chen
Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, China
4 shared publications
Latest Publications
- 13 November 2024
- Published by Wiley in International Journal of Cancer
- Vol. 156 (5) , 1033-1042
Disseminated intravascular coagulation is an underestimated but fatal adverse event associated with blinatumomab therapy: A pharmacovigilance analysis of FAERS
Hematologic adverse events (AEs) are common and serious toxicities in patients with hematologic malignancies undergoing blinatumomab therapy. However, restrictive selection criteria in pivotal clinical trials can lead to an underestimation of rare but fatal toxicities. In this study, we systematically analyzed hematologic AEs associated with blinatumomab using the Food and Drug Administration Adverse Event Reporting System (FAERS) from October 2014 to December 2023. Disproportionate analysis was performed to identify overreported AEs, with a reporting odds ratio (ROR), and a lower bound of the 95% confidence interval (ROR025) exceeding one considered significant. Additionally, adjusted mortality rates and risk ratios (RR) of the top 10 reported hematologic AEs were calculated using a logistic regression model. Among 4745 blinatumomab‐related cases, 418 (8.81%) involved hematologic AEs. We identified 22 significantly overreporting hematologic AEs compared to the full database, with myelosuppression (n = 39 [9.33%], ROR025 = 8.04), disseminated intravascular coagulation (DIC, n = 31 [7.42%], ROR025 = 15.14), and bone marrow failure (n = 14 [3.35%], ROR025 = 3.41) notably underestimated in clinical trials. DIC resulted in a substantial mortality rate of 45.16%. Finally, DIC was found to be independently associated with death in a multivariable logistic regression analysis (RR = 2.47 [95% CI: 1.11–3.83]). These findings could aid clinicians in the early detection of these rarely reported but fatal hematologic AEs, thereby reducing the risk of severe toxicities in blinatumomab recipients.
- 13 November 2024
- Published by Wiley in International Journal of Cancer
- Vol. 156 (5) , 1033-1042
Disseminated intravascular coagulation is an underestimated but fatal adverse event associated with blinatumomab therapy: A pharmacovigilance analysis of FAERS
Hematologic adverse events (AEs) are common and serious toxicities in patients with hematologic malignancies undergoing blinatumomab therapy. However, restrictive selection criteria in pivotal clinical trials can lead to an underestimation of rare but fatal toxicities. In this study, we systematically analyzed hematologic AEs associated with blinatumomab using the Food and Drug Administration Adverse Event Reporting System (FAERS) from October 2014 to December 2023. Disproportionate analysis was performed to identify overreported AEs, with a reporting odds ratio (ROR), and a lower bound of the 95% confidence interval (ROR025) exceeding one considered significant. Additionally, adjusted mortality rates and risk ratios (RR) of the top 10 reported hematologic AEs were calculated using a logistic regression model. Among 4745 blinatumomab‐related cases, 418 (8.81%) involved hematologic AEs. We identified 22 significantly overreporting hematologic AEs compared to the full database, with myelosuppression (n = 39 [9.33%], ROR025 = 8.04), disseminated intravascular coagulation (DIC, n = 31 [7.42%], ROR025 = 15.14), and bone marrow failure (n = 14 [3.35%], ROR025 = 3.41) notably underestimated in clinical trials. DIC resulted in a substantial mortality rate of 45.16%. Finally, DIC was found to be independently associated with death in a multivariable logistic regression analysis (RR = 2.47 [95% CI: 1.11–3.83]). These findings could aid clinicians in the early detection of these rarely reported but fatal hematologic AEs, thereby reducing the risk of severe toxicities in blinatumomab recipients.
- Open Access
- 15 March 2024
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 1-4
In vivo expression of anti-CD19/CD3 BiTE by liver-targeted AAV for the treatment of B cell malignancies
- 15 March 2024
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 1-4
Open AccessIn vivo expression of anti-CD19/CD3 BiTE by liver-targeted AAV for the treatment of B cell malignancies
- Open Access
- 31 January 2024
- Published by Springer Nature in Research Square
In vivo expression of anti-CD19/CD3 BiTE by liver-targeted AAV for the treatment of B cell malignancies
Anti-CD19/CD3 bispecific T-cell engagers (CD19BiTE) has shown promising efficacy in patients with relapsed or refractory (r/r) B-cell malignancies. However, the short half-life of CD19BiTE necessitates long-term repeated administration with rest period, which not only increases the costs but also compromises the efficacy. Long-term and stable expression of CD19BiTE is crucial for achieving durable responses of B-cell malignancies. Adeno-associated virus (AAV)-mediated gene therapy has been demonstrated to achieve long-term efficacy for multiple diseases. Here, we generated liver-targeted AAV encoding CD19BiTE (AAV-CD19BiTE) and achieved sustained expression of CD19BiTE for more than six months. The results indicated that AAV-CD19BiTE could significantly reduce the tumor burdens in CD19+ B-cell malignancies xenograft model via a single injection of AAV-CD19BiTE. Meanwhile, more CD3+, CD4+, CD8+T, and activated CD8+T cells were observed in lymphoma microenvironment after therapy with AAV-CD19BiTE. In addition, AAV-CD19BiTE was also proved to have a strong antitumor activity in patient-derived xenograft (PDX) model of B-cell lymphoma. Altogether, in vivo expression of CD19BiTE circumvents the problem of short half-life and may hold promise as a new therapeutical strategy for CD19+ B-cell malignancies via a single injection of AAV.
- 31 January 2024
- Published by Springer Nature in Research Square
Open AccessIn vivo expression of anti-CD19/CD3 BiTE by liver-targeted AAV for the treatment of B cell malignancies
Anti-CD19/CD3 bispecific T-cell engagers (CD19BiTE) has shown promising efficacy in patients with relapsed or refractory (r/r) B-cell malignancies. However, the short half-life of CD19BiTE necessitates long-term repeated administration with rest period, which not only increases the costs but also compromises the efficacy. Long-term and stable expression of CD19BiTE is crucial for achieving durable responses of B-cell malignancies. Adeno-associated virus (AAV)-mediated gene therapy has been demonstrated to achieve long-term efficacy for multiple diseases. Here, we generated liver-targeted AAV encoding CD19BiTE (AAV-CD19BiTE) and achieved sustained expression of CD19BiTE for more than six months. The results indicated that AAV-CD19BiTE could significantly reduce the tumor burdens in CD19+ B-cell malignancies xenograft model via a single injection of AAV-CD19BiTE. Meanwhile, more CD3+, CD4+, CD8+T, and activated CD8+T cells were observed in lymphoma microenvironment after therapy with AAV-CD19BiTE. In addition, AAV-CD19BiTE was also proved to have a strong antitumor activity in patient-derived xenograft (PDX) model of B-cell lymphoma. Altogether, in vivo expression of CD19BiTE circumvents the problem of short half-life and may hold promise as a new therapeutical strategy for CD19+ B-cell malignancies via a single injection of AAV.
- 6 November 2023
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (2) , 575-582
CEAC (oral semustine, etoposide, cytarabine and cyclophosphamide) vs BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimen of autologous stem cell transplantation for diffuse large B-cell lymphoma: a post-hoc, propensity score-matched, cohort study in Chinese patients
Autologous stem cell transplantation (ASCT) is a salvage therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). We have developed a novel conditioning regimen called CEAC (oral semustine 250 mg/m2 d-6, etoposide 300 mg/m2 d-5 ~ d-2, cytarabine 500 mg/m2 d-5 ~ d-2, and cyclophosphamide 1200 mg/m2 d-5 ~ d-2) In lymphoma patients in China. Here, we conducted a study to compare the conventional BEAM regimen with the CEAC regimen in 110 DLBCL patients. Propensity-score matching was performed in a 1:4 ratio (22 patients received BEAM and 88 received CEAC). Our results showed no significant difference in the overall response rate (95% vs 97%, P = 1.000) and complete response rate (66% vs 73%, P = 0.580) between the two cohorts. The 5-year progression-free survival (PFS), 5-year overall survival (OS), and 5-year cumulative incidence of relapse (CIR) for all patients were 72% (95% CI 62%–82%), 92% (95% CI 86%–97%), and 29% (95% CI 17%–38%), respectively. There was no significant difference in the 5-year PFS (80% vs 70%, P = 0.637), 5-year OS (95% vs 91%, P = 0.496), and 5-year CIR (20% vs 30%, P = 0.733) between cohorts. In terms of safety, the CEAC cohort had a lower incidence rate of grade 1–2 gastrointestinal hemorrhage (P = 0.023) and severe nausea (P = 0.007) compared with the BEAM cohort. In conclusion, the CEAC regimen seems to be a suitable alternative to the BEAM regimen for ASCT in DLBCL patients.
- 6 November 2023
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (2) , 575-582
CEAC (oral semustine, etoposide, cytarabine and cyclophosphamide) vs BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimen of autologous stem cell transplantation for diffuse large B-cell lymphoma: a post-hoc, propensity score-matched, cohort study in Chinese patients
Autologous stem cell transplantation (ASCT) is a salvage therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). We have developed a novel conditioning regimen called CEAC (oral semustine 250 mg/m2 d-6, etoposide 300 mg/m2 d-5 ~ d-2, cytarabine 500 mg/m2 d-5 ~ d-2, and cyclophosphamide 1200 mg/m2 d-5 ~ d-2) In lymphoma patients in China. Here, we conducted a study to compare the conventional BEAM regimen with the CEAC regimen in 110 DLBCL patients. Propensity-score matching was performed in a 1:4 ratio (22 patients received BEAM and 88 received CEAC). Our results showed no significant difference in the overall response rate (95% vs 97%, P = 1.000) and complete response rate (66% vs 73%, P = 0.580) between the two cohorts. The 5-year progression-free survival (PFS), 5-year overall survival (OS), and 5-year cumulative incidence of relapse (CIR) for all patients were 72% (95% CI 62%–82%), 92% (95% CI 86%–97%), and 29% (95% CI 17%–38%), respectively. There was no significant difference in the 5-year PFS (80% vs 70%, P = 0.637), 5-year OS (95% vs 91%, P = 0.496), and 5-year CIR (20% vs 30%, P = 0.733) between cohorts. In terms of safety, the CEAC cohort had a lower incidence rate of grade 1–2 gastrointestinal hemorrhage (P = 0.023) and severe nausea (P = 0.007) compared with the BEAM cohort. In conclusion, the CEAC regimen seems to be a suitable alternative to the BEAM regimen for ASCT in DLBCL patients.
- 9 February 2022
- Published by Wiley in Hematological Oncology
- Vol. 40 (4) , 637-644
Chimeric antigen receptor T‐cell therapy combined with autologous stem cell transplantation improved progression‐free survival of relapsed or refractory diffuse large B‐cell lymphoma patients: A single‐center, retrospective, cohort study
Autologous hematopoietic stem cell transplantation (ASCT) and chimeric antigen receptor T‐cell therapy (CART) are salvage therapies that are utilised for treatment of relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL). However, whether the combination therapy of ASCT and CART (ASCT‐CART) can improve the survival of R/R DLBCL remains unknown. Overall, 67 R/R DLBCL patients were included, among which 21 patients underwent ASCT‐CART therapy and 46 patients underwent ASCT therapy. The median number of mononuclear cells numbers that were infused in the ASCT‐CART and ASCT groups was 4.71 × 108/kg and 5.36 × 108/kg, respectively (p = 0.469). The median number of CD34+ cell numbers that were infused in the ASCT‐CART and ASCT groups was 2.41 × 106/kg and 3.05 × 106/kg, respectively (p = 0.663). The median number of CART cells that were infused was 2.63 × 106/kg with a median transduction rate of 59.83%. The objective response rates to ASCT‐CART and ASCT therapy were 90% and 89%, respectively (p = 1.000). However, the ASCT‐CART group showed higher complete remission (CR) rates than the ASCT group (71% vs. 33%; p = 0.003). The ASCT‐CART group demonstrated superior 3 year progression‐free survival (PFS) (80% vs. 44%; p = 0.036) and lower 3 year relapse/progression rate (15% vs. 56%; p = 0.015) compared to the ASCT group. However, the 3 year overall survival results indicated that there were no differences between the two groups (80% vs. 69%; p = 0.545). For R/R DLBCL patients, ASCT‐CART therapy is associated with higher CR rate, better PFS, and lower relapse/progression rate. These data support that ASCT‐CART therapy can be used as a salvage therapy for R/R DLBCL patients.
- 9 February 2022
- Published by Wiley in Hematological Oncology
- Vol. 40 (4) , 637-644
Chimeric antigen receptor T‐cell therapy combined with autologous stem cell transplantation improved progression‐free survival of relapsed or refractory diffuse large B‐cell lymphoma patients: A single‐center, retrospective, cohort study
Autologous hematopoietic stem cell transplantation (ASCT) and chimeric antigen receptor T‐cell therapy (CART) are salvage therapies that are utilised for treatment of relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL). However, whether the combination therapy of ASCT and CART (ASCT‐CART) can improve the survival of R/R DLBCL remains unknown. Overall, 67 R/R DLBCL patients were included, among which 21 patients underwent ASCT‐CART therapy and 46 patients underwent ASCT therapy. The median number of mononuclear cells numbers that were infused in the ASCT‐CART and ASCT groups was 4.71 × 108/kg and 5.36 × 108/kg, respectively (p = 0.469). The median number of CD34+ cell numbers that were infused in the ASCT‐CART and ASCT groups was 2.41 × 106/kg and 3.05 × 106/kg, respectively (p = 0.663). The median number of CART cells that were infused was 2.63 × 106/kg with a median transduction rate of 59.83%. The objective response rates to ASCT‐CART and ASCT therapy were 90% and 89%, respectively (p = 1.000). However, the ASCT‐CART group showed higher complete remission (CR) rates than the ASCT group (71% vs. 33%; p = 0.003). The ASCT‐CART group demonstrated superior 3 year progression‐free survival (PFS) (80% vs. 44%; p = 0.036) and lower 3 year relapse/progression rate (15% vs. 56%; p = 0.015) compared to the ASCT group. However, the 3 year overall survival results indicated that there were no differences between the two groups (80% vs. 69%; p = 0.545). For R/R DLBCL patients, ASCT‐CART therapy is associated with higher CR rate, better PFS, and lower relapse/progression rate. These data support that ASCT‐CART therapy can be used as a salvage therapy for R/R DLBCL patients.
- Open Access
- 5 February 2021
- Published by Springer Nature in Research Square
CD19 Chimeric Antigen Receptor T-cell Shows Activity in Patients with B-cell Lymphoma Without CD19 Expression by Immunohistochemistry
Background: Some clinical trials have reported that CD19-negative B-cell lymphoma patients responded to CD19 CART therapy. The mechanism of CD19 CART activating in patients with B-cell lymphoma that do not express CD19 by immunohistochemistry (IHC) remains unknown. Methods: 8 CART treated diffuse large B-cell lymphoma (DLBCL) patients and other 90 DLBCL tissues were tested by IHC using 7 anti-CD19 antibodies. Besides, CD19 mRNA and protein of 6 human DLBCL cell lines were assessed using Reverse Transcription Polymerase Chain Reaction (RT-PCR) and Western blotting analysis, and CD19 expression was evaluated by IHC as well as flow cytometry (FCM). Results: 6 out of 8 (75%) DLBCL patients who received CD19 CART therapy were identified as CD19-negative by at least one antibody. In the 6 patients, 5 objective responses were seen (response rate, 83.3%). For the 90 DLBCL samples, 68 samples were involved in analysis, and 57 out of 68 (83.8%) samples were assessed as CD19 negative by at least one antibody. IHC assay for 6 DLBCL cell lines showed that 3 cell lines CD19 expression by IHC had inconsistent results with CD19 mRNA and Western blotting assays, while FCM assay for the 6 DLBCL cell lines showed high sensitivity and good concordance to CD19 expression. Antibody HIB19 mean fluorescence intensity showed a positive correlation with CD19 expression (R2=0.8125, P=0.0137). Conclusion: These results demonstrate the mechanism that CD19-negaive B-cell lymphoma patients respond to CD19 CART therapy, suggesting that inclusion or exclusion of lymphoma patients for CD19 CART therapy based on current CD19 IHC seems unwarranted. FCM assay is recommended as a complementary diagnostic method to CD19 IHC.
- 5 February 2021
- Published by Springer Nature in Research Square
Open AccessCD19 Chimeric Antigen Receptor T-cell Shows Activity in Patients with B-cell Lymphoma Without CD19 Expression by Immunohistochemistry
Background: Some clinical trials have reported that CD19-negative B-cell lymphoma patients responded to CD19 CART therapy. The mechanism of CD19 CART activating in patients with B-cell lymphoma that do not express CD19 by immunohistochemistry (IHC) remains unknown. Methods: 8 CART treated diffuse large B-cell lymphoma (DLBCL) patients and other 90 DLBCL tissues were tested by IHC using 7 anti-CD19 antibodies. Besides, CD19 mRNA and protein of 6 human DLBCL cell lines were assessed using Reverse Transcription Polymerase Chain Reaction (RT-PCR) and Western blotting analysis, and CD19 expression was evaluated by IHC as well as flow cytometry (FCM). Results: 6 out of 8 (75%) DLBCL patients who received CD19 CART therapy were identified as CD19-negative by at least one antibody. In the 6 patients, 5 objective responses were seen (response rate, 83.3%). For the 90 DLBCL samples, 68 samples were involved in analysis, and 57 out of 68 (83.8%) samples were assessed as CD19 negative by at least one antibody. IHC assay for 6 DLBCL cell lines showed that 3 cell lines CD19 expression by IHC had inconsistent results with CD19 mRNA and Western blotting assays, while FCM assay for the 6 DLBCL cell lines showed high sensitivity and good concordance to CD19 expression. Antibody HIB19 mean fluorescence intensity showed a positive correlation with CD19 expression (R2=0.8125, P=0.0137). Conclusion: These results demonstrate the mechanism that CD19-negaive B-cell lymphoma patients respond to CD19 CART therapy, suggesting that inclusion or exclusion of lymphoma patients for CD19 CART therapy based on current CD19 IHC seems unwarranted. FCM assay is recommended as a complementary diagnostic method to CD19 IHC.
- 5 August 2020
- Published by Taylor & Francis in Immunotherapy
- Vol. 12 (13) , 997-1006
Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Aim: Autologous hematopoietic stem cell transplantation (ASCT) is the standard-of-care curative treatment for relapsed or refractory diffuse large B-cell lymphoma (RR-DLBCL), but the relapse rate i...
- 5 August 2020
- Published by Taylor & Francis in Immunotherapy
- Vol. 12 (13) , 997-1006
Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Aim: Autologous hematopoietic stem cell transplantation (ASCT) is the standard-of-care curative treatment for relapsed or refractory diffuse large B-cell lymphoma (RR-DLBCL), but the relapse rate i...